Search research articles
Contact Us
Filters
Showing results (951-960 of 1,012) with videos related to
Page
of 102
Sort By:
Frontiers in Oncology
|
April 4, 2022
Physicians' Perceptions of Clinical Utility of a Digital Health Tool for Electronic Patient-Reported Outcome Monitoring in Real-Life Hematology Practice. Evidence From the GIMEMA-ALLIANCE Platform
Fabio Efficace, Andrea Patriarca, Mario Luppi, et al.
Bone Marrow Transplantation
|
July 2, 2026
Early software-assisted response predicts survival in a prospective cohort of 258 newly diagnosed cGvHD patients
Attilio Olivieri, Giorgia Mancini, Jacopo Olivieri, et al.
British Journal of Haematology
|
August 26, 2025
Real-world efficacy and safety of fostamatinib in ITP patients: Italian multicentre experience. GIMEMA ITP1122 study
Elisa Lucchini, Nicola Vianelli, Ugo Consoli, et al.
American Journal of Hematology
|
May 26, 2022
Treosulfan compared with reduced-intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: Final analysis of a prospective randomized trial
Dietrich W Beelen, Matthias Stelljes, Péter Reményi, et al.
The Lancet. Oncology
|
October 3, 2015
Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial
Alessandro Rambaldi, Anna Grassi, Arianna Masciulli, et al.
Leukemia
|
June 5, 2014
Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors
J Peccatori, A Forcina, D Clerici, et al.
Transplantation and Cellular Therapy
|
November 24, 2021
GITMO Registry Study on Allogeneic Transplantation in Patients Aged ≥60 Years from 2000 to 2017: Improvements and Criticisms
Michele Malagola, Nicola Polverelli, Vicky Rubini, et al.
Blood Advances
|
February 10, 2025
Posttransplant cyclophosphamide as GVHD prophylaxis in patients receiving mismatched unrelated HCT: the PHYLOS trial
Anna Maria Raiola, Benedetto Bruno, Antonio Maria Risitano, et al.
American Journal of Hematology
|
June 6, 2025
Long-Term Outcome of Fanconi Anemia Patients From the Italian Registry on Behalf of the Marrow Failure Study Group of the AIEOP (Italian Association for Pediatric Haematology-Oncology)
Erica Ricci, Francesca Bagnasco, Filomena Pierri, et al.
Transplantation Direct
|
February 27, 2023
Busulfan or Treosulfan Conditioning Platform for Allogeneic Stem Cell Transplantation in Patients Aged >60 Y With Acute Myeloid Leukemia/Myelodysplastic Syndrome: A Subanalysis of the GITMO AlloEld Study
Michele Malagola, Nicola Polverelli, Massimo Martino, et al.
Page
of 102
Search research articles
Search
Showing results (951-960 of 1,012) with videos related to
Sort By:
Page
of 102
Frontiers in Oncology
|
April 4, 2022
Physicians' Perceptions of Clinical Utility of a Digital Health Tool for Electronic Patient-Reported Outcome Monitoring in Real-Life Hematology Practice. Evidence From the GIMEMA-ALLIANCE Platform
Fabio Efficace, Andrea Patriarca, Mario Luppi, et al.
Bone Marrow Transplantation
|
July 2, 2026
Early software-assisted response predicts survival in a prospective cohort of 258 newly diagnosed cGvHD patients
Attilio Olivieri, Giorgia Mancini, Jacopo Olivieri, et al.
British Journal of Haematology
|
August 26, 2025
Real-world efficacy and safety of fostamatinib in ITP patients: Italian multicentre experience. GIMEMA ITP1122 study
Elisa Lucchini, Nicola Vianelli, Ugo Consoli, et al.
American Journal of Hematology
|
May 26, 2022
Treosulfan compared with reduced-intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: Final analysis of a prospective randomized trial
Dietrich W Beelen, Matthias Stelljes, Péter Reményi, et al.
The Lancet. Oncology
|
October 3, 2015
Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial
Alessandro Rambaldi, Anna Grassi, Arianna Masciulli, et al.
Leukemia
|
June 5, 2014
Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors
J Peccatori, A Forcina, D Clerici, et al.
Transplantation and Cellular Therapy
|
November 24, 2021
GITMO Registry Study on Allogeneic Transplantation in Patients Aged ≥60 Years from 2000 to 2017: Improvements and Criticisms
Michele Malagola, Nicola Polverelli, Vicky Rubini, et al.
Blood Advances
|
February 10, 2025
Posttransplant cyclophosphamide as GVHD prophylaxis in patients receiving mismatched unrelated HCT: the PHYLOS trial
Anna Maria Raiola, Benedetto Bruno, Antonio Maria Risitano, et al.
American Journal of Hematology
|
June 6, 2025
Long-Term Outcome of Fanconi Anemia Patients From the Italian Registry on Behalf of the Marrow Failure Study Group of the AIEOP (Italian Association for Pediatric Haematology-Oncology)
Erica Ricci, Francesca Bagnasco, Filomena Pierri, et al.
Transplantation Direct
|
February 27, 2023
Busulfan or Treosulfan Conditioning Platform for Allogeneic Stem Cell Transplantation in Patients Aged >60 Y With Acute Myeloid Leukemia/Myelodysplastic Syndrome: A Subanalysis of the GITMO AlloEld Study
Michele Malagola, Nicola Polverelli, Massimo Martino, et al.
Page
of 102